Supercharged donor cells battle aggressive leukemia in groundbreaking trial
NCT ID NCT05580601
Summary
This study is testing a new cell therapy for people with acute myeloid leukemia (AML) that has returned or not responded to standard treatments. Doctors take immune cells from a partially matched family donor, activate them in a lab, and infuse them into the patient after a short course of chemotherapy. The main goals are to see if this treatment is safe and if it can help control the leukemia enough for patients to later receive a stem cell transplant.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cincinnati Children's Hospital Medical Center
RECRUITINGCincinnati, Ohio, 45229, United States
Contact Email: •••••@•••••
Contact
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.